Highest development stage: Phase 3

Development status: Inactive

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: An analogue of ciprofloxacin designed for enhanced activity against Gram positives (1). This is effective against multi drug resistant infections (2)

Reason dropped: Due to concerns of adverse effects, this was discontinued at registration phase. However, according to AdisInsight this may become marketed later as Pfizer are seeking compassionate designation usage as this was for a last lline defense (1)